Breakthrough trial tests First-Ever monthly shots to control HIV
NCT ID NCT02938520
Summary
This large, late-stage study is testing if switching from daily HIV pills to a combination of two long-acting drugs given as a monthly injection can keep the virus under control. It involved over 600 adults whose HIV was already well-managed on daily medication. The main goal is to see if the monthly shots work as well as the daily pills over 48 weeks.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV INFECTIONS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
GSK Investigational Site
Long Beach, California, 90813, United States
-
GSK Investigational Site
Los Angeles, California, 90019, United States
-
GSK Investigational Site
Los Angeles, California, 90027, United States
-
GSK Investigational Site
Augusta, Georgia, 30912-3130, United States
-
GSK Investigational Site
Macon, Georgia, 31201, United States
-
GSK Investigational Site
Austin, Texas, 78705, United States
-
GSK Investigational Site
Bellaire, Texas, 77401, United States
-
GSK Investigational Site
Dallas, Texas, 75246, United States
-
GSK Investigational Site
Fort Worth, Texas, 76104, United States
-
GSK Investigational Site
Aichi, 460-0001, Japan
-
GSK Investigational Site
Osaka, 540-0006, Japan
-
GSK Investigational Site
Tokyo, 162-8655, Japan
-
GSK Investigational Site
Kazan', 420061, Russia
-
GSK Investigational Site
Kemerovo, 650056, Russia
-
GSK Investigational Site
Krasnodar, 350015, Russia
-
GSK Investigational Site
Lipetsk, 398043, Russia
-
GSK Investigational Site
Moscow, 115035, Russia
-
GSK Investigational Site
Oryol, 302040, Russia
-
GSK Investigational Site
Saint Petersburg, 190020, Russia
-
GSK Investigational Site
Saint Petersburg, 193167, Russia
-
GSK Investigational Site
Saint Petersburg, 196645, Russia
-
GSK Investigational Site
Saratov, 410009, Russia
-
GSK Investigational Site
Smolensk, 214006, Russia
-
GSK Investigational Site
Toliyatti, 445846, Russia
-
GSK Investigational Site
Yekaterinburg, 620102, Russia
-
GSK Investigational Site
Bloemfontein, 9301, South Africa
-
GSK Investigational Site
Cape Town, 7925, South Africa
-
GSK Investigational Site
Durban, 4052, South Africa
-
GSK Investigational Site
Durban, 4091, South Africa
-
GSK Investigational Site
Johannesburg, 2113, South Africa
-
GSK Investigational Site
Middelburg, 1055, South Africa
-
GSK Investigational Site
Pretoria, 0087, South Africa
-
GSK Investigational Site
Ferrol, 15405, Spain
-
GSK Investigational Site
Granada, 18016, Spain
-
GSK Investigational Site
La Laguna Santa Cruz, 38320, Spain
-
GSK Investigational Site
Madrid, 28041, Spain
-
GSK Investigational Site
Madrid, 28046, Spain
-
GSK Investigational Site
Murcia, 30003, Spain
-
GSK Investigational Site
San SebastiAn de Los Rey, 28702, Spain
-
GSK Investigational Site
Santa Cruz de Tenerife, 38010, Spain
-
GSK Investigational Site
Santander, 39008, Spain
-
GSK Investigational Site
Birmingham, B9 5SS, United Kingdom
-
GSK Investigational Site
Leeds Yorkshire, LS1 3EX, United Kingdom
-
GSK Investigational Site
London, E1 1BB, United Kingdom
Conditions
Explore the condition pages connected to this study.